

FOR IMMEDIATE RELEASE

Sun Pharma introduces a novel treatment, STARIZO (Tedizolid Phosphate) in India for acute bacterial skin and skin structure infections

MUMBAI, India, August 23, 2024: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that it has launched Tedizolid Phosphate tablets 200 mg in India under the brand name “STARIZO”. STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI).

Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India.

“Drug-resistant bacteria such as methicillin-resistant *Staphylococcus aureus* (MRSA) causing ABSSSIs, are more challenging to treat due to the limited availability of effective treatment options in hospitals.^[i] With STARIZO, we are introducing a treatment option which is effective and has the convenience of once-a-day dosing”, said Kirti Ganorkar, CEO - India Business, Sun Pharma. “At Sun Pharma, it has always been our endeavour to introduce innovative medicines that help improve the quality of life of patients,” he added.

Skin and soft tissue infections are the most common type of infections constituting, around 29-32% of all infections in 2018-2019 in India.^[ii] The treatment of ABSSSI is further complicated with associated comorbidities such as diabetes, obesity, renal and hepatic dysfunction in these patients.^[iii]

The incidence of invasive *S. aureus* infections has increased over the past decades and is associated with poor outcomes and high mortality rates. *S. aureus* is responsible for almost one-third of ABSSSIs, with MRSA accounting for a large proportion of these.^[iv] MRSA rates in India have been increasing each year from 28.4% in 2016 to 42.6% in 2021 (*S. aureus* infections).^[v] Drug-resistant bacteria such as MRSA causing ABSSSIs, are more challenging to treat due to the limited availability of effective antibiotics.^[vi]

STARIZO (Tedizolid Phosphate) is a once-a-day oral treatment for six days compared to the current standard of care which has to be given twice daily for 10-14 days. STARIZO (Tedizolid Phosphate) has demonstrated activity against gram-positive organisms, including MRSA. STARIZO (Tedizolid) provides the advantage of reduced frequency and duration of drug administration. STARIZO (Tedizolid Phosphate) requires no dose adjustment in the elderly, patients with hepatic or renal impairment and patients on haemodialysis.^[vii]

Tedizolid Phosphate is sold in India under a licensing agreement with MERCK SHARP & DOHME SINGAPORE TRADING PTE. LTD.

Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)

Sun Pharma is a leading global specialty generics company with presence in Innovative products, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on [LinkedIn](#) & [X](#) (Formerly Twitter).”

Disclaimer

Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward-looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Contacts

Investors

Dr. Abhishek Sharma

Tel + 91 22 4324 4324, Ext 2929

Tel Direct + 91 22 43242929

Mobile + 91 98196 86016

E mail abhi.sharma@sunpharma.com

Media

Gaurav Chugh

Tel + 91 22 4324 4324, Ext 5373

Tel Direct + 91 22 43245373

Mobile + 91 98104 71414

E mail gaurav.chugh@sunpharma.com